跳至主要内容
临床试验/NCT00521131
NCT00521131已完成4 期

Evaluation of Efficacy, Using the Number of Comfortable Days and the Safety of Levocetirizine Dihydrochloride, Administered Once Daily in the Evening for 30 Days, to Subjects Suffering From Perennial Allergic Rhinitis to House Dust Mites

UCB Pharma0 个研究点目标入组 453 人开始时间: 2002年9月最近更新:
适应症
相关药物

试验速览

阶段
4 期
状态
已完成
发起方
UCB Pharma
入组人数
453
主要终点
Number of comfortable days, as assessed by the subject

研究概览

简要总结

Evaluation of Efficacy and Safety of Levocetirizine to Subjects With Perennial Allergic Rhinitis to House Dust Mites

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Double

入排标准

年龄范围
12 Years 至 —(Child, Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • male or female ≥ 12 years
  • suffering from a perennial allergic rhinitis to house dust mites for at least 2 years
  • positive skin test or positive Radio-Allergo-Sorbent-Test for house dust mites
  • the mean of the T4SS evaluated in the evening over the last 24 hours of the selection period was ≥ 5

排除标准

  • seasonal allergic rhinitis likely to change significantly the symptoms of the subject
  • an ear, nose or throat (ENT) infection during the two weeks preceding initial visit
  • asthma requiring corticosteroid treatment
  • atopic dermatitis or urticaria requiring an antihistamine treatment or the administration of oral or topical corticosteroids
  • associated ENT disease

结局指标

主要结局

Number of comfortable days, as assessed by the subject

时间窗: 30 days

次要结局

  • Sum of 4 and 5 rhinitis symptoms and safety(Week 1 and over 30 days)

研究者

发起方
UCB Pharma
申办方类型
Industry

相似试验